26-May-2016 — AFSTYLA® [Antihaemophilic Factor (Recombinant), Single Chain], CSL Behring’s novel long-lasting recombinant factor VIII single-chain therapy for adults and children with haemophilia A. More.
24-May-2016 — The four-strain, cell culture-derived, inactivated seasonal influenza vaccine is produced at our full-scale cell culture influenza vaccine manufacturing facility in Holly Springs, North Carolina. More.
Other recent news:
12-May-2016 — The European Commission has now approved IDELVION for the treatment and prophylaxis of bleeding in patients with haemophilia B. More.
25-Apr-2016 — CSL officially celebrates 100 years of operation on 25th April 2016. More.
14-Apr-2016 — CSL is proud to announce the establishment of a new flagship $25 million fellowship program for early stage and translational research in Australia. More.